Money Talks: Why weight-loss drugs will resha...

We examine the record of the man at the helm of India’s government. As protests pose a fresh threat, where will he take the country next? From New Hampshire to Virginia, our American-midterms series takes you to the races you might be missing. And the life of Winston Churchill’s ...  Show more

The world’s richest person does not say much nice about philanthropy, and his foundation does not say much about itself. Our correspondent digs deeper. The next stop for our midterm-elections series is Kansas, where a Republican-seeming Democrat has an unlikely shot at the Senate ...  Show more

More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs th ...

It’s become a multibillion-dollar business: weight loss drugs. Demand is high, as is the cost. How did medications like Ozempic, Wegovy, Mounjaro and Zepbound become so popular and so profitable? And what kind of impact might they have on the future of food and healthcare? Dr. Sa ...  Show more

Weight-loss drugs have become a golden formula for pharma growth. In this episode we speak to Sector Advisor Maria Latorre and Senior Economist Michaela Grimm about how GLP-1 treatments like Ozempic and Wegovy are reshaping the industry, and the risks that lie ahead. SHOWNOTES: • ...  Show more